RxDoctor Payments Data

Mary Evans

Nurse Practitioner · Montgomery, ALNPI 1508948340

Payments from drug & device makers

$3,597in general payments, 2019–2025

Across 198 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$405
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$371
  • Sumitomo Pharma America, Inc.$314
  • AbbVie$310
  • Otsuka America Pharmaceutical, Inc.$203
  • Lilly USA, LLC$174
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$3,51798%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,597 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$30,194
Medicare patients
175
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$30,401
MounjaroTirzepatide11$15,964
JardianceEmpagliflozin12$9,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,392
MyrbetriqMirabegron13$5,696
Tizanidine Hcl29$934
Memantine Hcl21$850
Albuterol Sulfate HfaAlbuterol Sulfate37$794
Atorvastatin Calcium77$793
Pantoprazole Sodium54$792
Losartan Potassium59$716
Trazodone Hcl41$711
Fluticasone Propionate33$693
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$680
Levothyroxine Sodium51$636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$30,40132 claims
Lilly USA, LLCMounjaro$174$15,96411 claims
GSKTrelegy Ellipta$95$8,39213 claims
Astellas Pharma US IncMyrbetriq$152$5,69613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →